Relay Therapeutics Income Statement (2020-2025) | RLAY

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
0.95M0.84M0.67M0.57M0.42M0.36M0.34M0.25M0.23M0.12M25.20M-0.00M10.01M7.68M0.68M7.00M
Operating items
Research & Development (Quarter)
30.62M45.15M44.97M51.91M51.67M60.51M66.90M67.28M82.83M88.20M81.49M77.50M82.40M91.99M76.62M68.08M73.81M63.90M68.26M55.41M
Selling, General & Administrative (Quarter)
12.73M14.42M14.68M15.55M16.07M17.46M16.07M16.37M19.58M20.12M18.48M16.77M19.80M20.14M19.75M16.90M18.74M13.63M12.13M12.21M
Other Operating Expenses (Quarter)
134.85M2.00M0.84M-4.59M0.20M3.26M-10.54M-1.00M-2.15M-1.20M-2.07M-1.83M-11.37M
Operating Expenses (Quarter)
43.36M194.42M61.66M68.29M63.14M78.18M86.24M73.10M101.40M106.17M98.78M92.19M100.37M100.76M96.37M84.98M92.55M77.52M80.39M67.63M
Operating Income (Quarter)
-42.41M-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M
EBIT (Quarter)
-42.41M-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M
Non-operating items
Interest & Investment Income (Quarter)
0.23M0.18M0.16M0.27M0.70M1.00M1.71M5.37M6.94M7.56M7.84M8.70M8.95M8.55M8.27M8.97M7.81M7.11M6.41M5.71M
Other Non Operating Income (Quarter)
0.22M0.18M0.16M0.27M0.68M1.02M1.72M5.35M6.94M7.54M7.84M8.70M8.98M8.54M8.26M8.97M7.80M6.47M6.24M5.74M
Non Operating Income (Quarter)
0.22M0.18M0.16M0.83M0.68M0.02M1.72M-0.02M6.94M-0.01M-0.00M0.00M0.03M-0.00M8.26M8.97M7.80M6.47M6.24M0.03M
Net income details
EBT (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M
Profit After Tax (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.79M-84.17M-67.50M-94.24M-98.50M-65.73M-83.50M-81.39M-92.21M-88.11M-76.00M-77.06M-70.38M-74.15M-54.89M
Income from Continuing Operations (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M
Consolidated Net Income (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M
Income towards Parent Company (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-42.18M-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M
Additional items
EPS (Basic) (Quarter)
-0.47-2.10-0.66-0.62-0.57-0.71-0.76-0.55-0.78-0.81-0.54-0.67-0.62-0.69-0.63-0.42-0.46-0.41-0.43-0.31
EPS (Weighted Average and Diluted) (Quarter)
-0.66-0.62-0.57-0.71-0.76-0.55-0.78-0.81-0.54-0.67-0.62-0.69-0.63-0.42-0.46-0.41-0.43-0.31
Shares Outstanding (Weighted Average) (Quarter)
90.20M91.94M92.60M95.14M108.29M108.47M110.91M112.23M121.32M121.68M122.23M122.58M130.84M131.83M140.23M142.87M169.23M171.26M172.39M171.59M
Shares Outstanding (Diluted Average) (Quarter)
92.60M109.29M
EBITDA (Quarter)
-42.24M-193.47M-60.76M-68.55M-70.18M-79.48M-85.66M-64.53M-89.62M-98.78M-63.04M-80.31M-82.35M-92.39M-84.26M-79.50M-76.04M-70.58M-73.49M-54.65M
Interest Expenses (Quarter)
0.01M0.02M0.00M
Shares Outstanding (Quarter)
90.43M92.55M92.80M108.21M108.43M108.81M120.81M121.11M121.48M121.94M123.16M127.46M132.30M133.32M166.89M167.76M170.48M171.69M172.63M173.87M